Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod

A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.